LCL161
LCL161 is a pharmaceutical drug with 8 clinical trials. Historical success rate of 85.7%.
Success Metrics
Based on 6 completed trials
Phase Distribution
Phase Distribution
7
Early Stage
1
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 2Trial Status & Enrollment
85.7%
6 of 7 finished
14.3%
1 ended early
0
trials recruiting
8
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
LCL161 Plus Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic Malignancies
A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat
Study of Single Agent CJM112, and PDR001 in Combination With LCL161 or CJM112 in Patients With Multiple Myeloma
A Study of LCL161 in Combination With Weekly Paclitaxel in Adult Patients With Advanced Solid Tumors
Safety and Tolerability of Oral LCL161 in Japanese Adult Patients With Advanced Solid Tumors
Clinical Trials (8)
LCL161 Plus Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic Malignancies
A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat
Study of Single Agent CJM112, and PDR001 in Combination With LCL161 or CJM112 in Patients With Multiple Myeloma
A Study of LCL161 in Combination With Weekly Paclitaxel in Adult Patients With Advanced Solid Tumors
Safety and Tolerability of Oral LCL161 in Japanese Adult Patients With Advanced Solid Tumors
A Randomized, Phase 2, Neoadjuvant Study of Weekly Paclitaxel With or Without LCL161 in Patients With Triple Negative Breast Cancer
Phase I Trial of LCL161 and Gemcitabine Plus Nab-Paclitaxel in Metastatic Pancreatic Cancer
Safety and Efficacy of LCL161 in Patients With Solid Tumors
All 8 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 8